The overall objective of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to improve our understanding of cancer biology by conducting proteogenomic analysis on selected cancer types where unanswered questions remain about the molecular biology of the disease. This analysis will add a complementary layer of protein molecular biology that facilitates refinement of driver genes, enhances understanding of the pathogenesis through proteomic subtyping, and illuminates dynamic alterations in posttranslational modifications (PTMs) responsible for the dysregulation of cancer signaling networks and pathways.